Baseline clinical characteristics for the 10 patients
| Characteristic | Number (%) or median (range) |
|---|---|
| Gender | |
| Male, n (%) | 4 (40%) |
| Female, n (%) | 6 (60%) |
| Age in years, median (range) | 22.9 (20–62) |
| Race | |
| White, n (%) | 6 (60%) |
| Black, n (%) | 2 (20%) |
| Asian, n (%) | 1 (10%) |
| Multiracial, n (%) | 1 (10%) |
| Medications | |
| Albuterol, prn inhaled, n (%) | 9 (90%) |
| Fluticasone, inhaled, n (%) | 2 (20%) |
| Fluticasone/salmetrol, inhaled, n (%) | 1 (10%) |
| Montelukast, oral, n (%) | 2 (20%) |
| Cetirizine, oral, n (%) | 1 (10%) |
| Loratidine, oral, n (%) | 1 (10%) |
| Diphenhydramine, oral, n (%) | 1 (10%) |
| Topical hydrocortisone | 1 (10%) |
| FEV1, % predicted, median (range) | 88.5 (73–108) |
| Frequency of rescue inhaler use in prior 3 months, n, median (range) | 0 (0–12) |